Experimental study shows BET inhibition alleviates inflammation in secondary hemophagocytic lymphohistiocytosis mice, suggesting therapeutic potential.
Key Points
This research investigates the role of BET inhibition in treating secondary hemophagocytic lymphohistiocytosis (HLH) in a mouse model.
Induced HLH in C57BL/6 mice using CpG 1826 and anti-IL-10 receptor antibody.
Treated HLH with OPN-51107 or vehicle and measured outcomes at day 9.
Analyzed organ weights, blood counts, and cytokine levels; used flow cytometry for immune cell assessment.
HLH induced significant hepatosplenomegaly and cytopenia in vehicle-treated mice compared to healthy controls.
OPN-51107 treatment significantly reduced hepatosplenomegaly and improved red blood cell counts in HLH mice.
Cytokine levels of IFN-γ, IL-6, and IL-18 decreased significantly in BET inhibitor treated HLH mice compared to vehicle.